Antiplatelet Therapy After Noncardioembolic Stroke

Jacoba P. Greving, Hans Christoph Diener, Johannes B. Reitsma, Philip M. Bath, László Csiba, Werner Hacke, L. Jaap Kappelle, Peter J. Koudstaal, Didier Leys, Jean Louis Mas, Ralph L Sacco, Ale Algra

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical characteristics. Methods- We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results- Aspirin/dipyridamole combination (RRNMA-adj, 0.83; 95% CI, 0.74-0.94) significantly reduced the risk of vascular events compared with aspirin, as did clopidogrel (RRNMA-adj, 0.88; 95% CI, 0.78-0.98), and aspirin/clopidogrel combination (RRNMA-adj, 0.83; 95% CI, 0.71-0.96). Clopidogrel caused significantly less major bleeding and intracranial hemorrhage than aspirin, aspirin/dipyridamole combination, and aspirin/clopidogrel combination. Aspirin/clopidogrel combination caused significantly more major bleeding than aspirin, aspirin/dipyridamole combination, and clopidogrel. Net clinical benefit was similar for clopidogrel and aspirin/dipyridamole combination (RRNMA-adj, 0.99; 95% CI, 0.93-1.05). Subgroup analyses showed no heterogeneity of treatment effectiveness across prespecified subgroups. The excess risk of major bleeding associated with aspirin/clopidogrel combination compared with clopidogrel alone was higher in patients aged <65 years than it was in patients ≥65 years (RRNMA-adj, 3.9 versus 1.7). Conclusions- Results favor clopidogrel and aspirin/dipyridamole combination for long-term secondary prevention after noncardioembolic stroke or transient ischemic attack, regardless of patient characteristics. Aspirin/clopidogrel combination was associated with a significantly higher risk of major bleeding compared with other antiplatelet regimens.

Original languageEnglish (US)
Pages (from-to)1812-1818
Number of pages7
JournalStroke
Volume50
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

clopidogrel
Aspirin
Stroke
Dipyridamole
Hemorrhage
Blood Vessels
Therapeutics
Transient Ischemic Attack
Platelet Aggregation Inhibitors
Secondary Prevention

Keywords

  • antiplatelet agents
  • efficacy
  • myocardial infarction
  • secondary prevention
  • stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine
  • Advanced and Specialized Nursing

Cite this

Greving, J. P., Diener, H. C., Reitsma, J. B., Bath, P. M., Csiba, L., Hacke, W., ... Algra, A. (2019). Antiplatelet Therapy After Noncardioembolic Stroke. Stroke, 50(7), 1812-1818. https://doi.org/10.1161/STROKEAHA.118.024497

Antiplatelet Therapy After Noncardioembolic Stroke. / Greving, Jacoba P.; Diener, Hans Christoph; Reitsma, Johannes B.; Bath, Philip M.; Csiba, László; Hacke, Werner; Kappelle, L. Jaap; Koudstaal, Peter J.; Leys, Didier; Mas, Jean Louis; Sacco, Ralph L; Algra, Ale.

In: Stroke, Vol. 50, No. 7, 01.07.2019, p. 1812-1818.

Research output: Contribution to journalArticle

Greving, JP, Diener, HC, Reitsma, JB, Bath, PM, Csiba, L, Hacke, W, Kappelle, LJ, Koudstaal, PJ, Leys, D, Mas, JL, Sacco, RL & Algra, A 2019, 'Antiplatelet Therapy After Noncardioembolic Stroke', Stroke, vol. 50, no. 7, pp. 1812-1818. https://doi.org/10.1161/STROKEAHA.118.024497
Greving JP, Diener HC, Reitsma JB, Bath PM, Csiba L, Hacke W et al. Antiplatelet Therapy After Noncardioembolic Stroke. Stroke. 2019 Jul 1;50(7):1812-1818. https://doi.org/10.1161/STROKEAHA.118.024497
Greving, Jacoba P. ; Diener, Hans Christoph ; Reitsma, Johannes B. ; Bath, Philip M. ; Csiba, László ; Hacke, Werner ; Kappelle, L. Jaap ; Koudstaal, Peter J. ; Leys, Didier ; Mas, Jean Louis ; Sacco, Ralph L ; Algra, Ale. / Antiplatelet Therapy After Noncardioembolic Stroke. In: Stroke. 2019 ; Vol. 50, No. 7. pp. 1812-1818.
@article{d833f820947041e282ed4f464c9d280a,
title = "Antiplatelet Therapy After Noncardioembolic Stroke",
abstract = "Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical characteristics. Methods- We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results- Aspirin/dipyridamole combination (RRNMA-adj, 0.83; 95{\%} CI, 0.74-0.94) significantly reduced the risk of vascular events compared with aspirin, as did clopidogrel (RRNMA-adj, 0.88; 95{\%} CI, 0.78-0.98), and aspirin/clopidogrel combination (RRNMA-adj, 0.83; 95{\%} CI, 0.71-0.96). Clopidogrel caused significantly less major bleeding and intracranial hemorrhage than aspirin, aspirin/dipyridamole combination, and aspirin/clopidogrel combination. Aspirin/clopidogrel combination caused significantly more major bleeding than aspirin, aspirin/dipyridamole combination, and clopidogrel. Net clinical benefit was similar for clopidogrel and aspirin/dipyridamole combination (RRNMA-adj, 0.99; 95{\%} CI, 0.93-1.05). Subgroup analyses showed no heterogeneity of treatment effectiveness across prespecified subgroups. The excess risk of major bleeding associated with aspirin/clopidogrel combination compared with clopidogrel alone was higher in patients aged <65 years than it was in patients ≥65 years (RRNMA-adj, 3.9 versus 1.7). Conclusions- Results favor clopidogrel and aspirin/dipyridamole combination for long-term secondary prevention after noncardioembolic stroke or transient ischemic attack, regardless of patient characteristics. Aspirin/clopidogrel combination was associated with a significantly higher risk of major bleeding compared with other antiplatelet regimens.",
keywords = "antiplatelet agents, efficacy, myocardial infarction, secondary prevention, stroke",
author = "Greving, {Jacoba P.} and Diener, {Hans Christoph} and Reitsma, {Johannes B.} and Bath, {Philip M.} and L{\'a}szl{\'o} Csiba and Werner Hacke and Kappelle, {L. Jaap} and Koudstaal, {Peter J.} and Didier Leys and Mas, {Jean Louis} and Sacco, {Ralph L} and Ale Algra",
year = "2019",
month = "7",
day = "1",
doi = "10.1161/STROKEAHA.118.024497",
language = "English (US)",
volume = "50",
pages = "1812--1818",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Antiplatelet Therapy After Noncardioembolic Stroke

AU - Greving, Jacoba P.

AU - Diener, Hans Christoph

AU - Reitsma, Johannes B.

AU - Bath, Philip M.

AU - Csiba, László

AU - Hacke, Werner

AU - Kappelle, L. Jaap

AU - Koudstaal, Peter J.

AU - Leys, Didier

AU - Mas, Jean Louis

AU - Sacco, Ralph L

AU - Algra, Ale

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical characteristics. Methods- We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results- Aspirin/dipyridamole combination (RRNMA-adj, 0.83; 95% CI, 0.74-0.94) significantly reduced the risk of vascular events compared with aspirin, as did clopidogrel (RRNMA-adj, 0.88; 95% CI, 0.78-0.98), and aspirin/clopidogrel combination (RRNMA-adj, 0.83; 95% CI, 0.71-0.96). Clopidogrel caused significantly less major bleeding and intracranial hemorrhage than aspirin, aspirin/dipyridamole combination, and aspirin/clopidogrel combination. Aspirin/clopidogrel combination caused significantly more major bleeding than aspirin, aspirin/dipyridamole combination, and clopidogrel. Net clinical benefit was similar for clopidogrel and aspirin/dipyridamole combination (RRNMA-adj, 0.99; 95% CI, 0.93-1.05). Subgroup analyses showed no heterogeneity of treatment effectiveness across prespecified subgroups. The excess risk of major bleeding associated with aspirin/clopidogrel combination compared with clopidogrel alone was higher in patients aged <65 years than it was in patients ≥65 years (RRNMA-adj, 3.9 versus 1.7). Conclusions- Results favor clopidogrel and aspirin/dipyridamole combination for long-term secondary prevention after noncardioembolic stroke or transient ischemic attack, regardless of patient characteristics. Aspirin/clopidogrel combination was associated with a significantly higher risk of major bleeding compared with other antiplatelet regimens.

AB - Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical characteristics. Methods- We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results- Aspirin/dipyridamole combination (RRNMA-adj, 0.83; 95% CI, 0.74-0.94) significantly reduced the risk of vascular events compared with aspirin, as did clopidogrel (RRNMA-adj, 0.88; 95% CI, 0.78-0.98), and aspirin/clopidogrel combination (RRNMA-adj, 0.83; 95% CI, 0.71-0.96). Clopidogrel caused significantly less major bleeding and intracranial hemorrhage than aspirin, aspirin/dipyridamole combination, and aspirin/clopidogrel combination. Aspirin/clopidogrel combination caused significantly more major bleeding than aspirin, aspirin/dipyridamole combination, and clopidogrel. Net clinical benefit was similar for clopidogrel and aspirin/dipyridamole combination (RRNMA-adj, 0.99; 95% CI, 0.93-1.05). Subgroup analyses showed no heterogeneity of treatment effectiveness across prespecified subgroups. The excess risk of major bleeding associated with aspirin/clopidogrel combination compared with clopidogrel alone was higher in patients aged <65 years than it was in patients ≥65 years (RRNMA-adj, 3.9 versus 1.7). Conclusions- Results favor clopidogrel and aspirin/dipyridamole combination for long-term secondary prevention after noncardioembolic stroke or transient ischemic attack, regardless of patient characteristics. Aspirin/clopidogrel combination was associated with a significantly higher risk of major bleeding compared with other antiplatelet regimens.

KW - antiplatelet agents

KW - efficacy

KW - myocardial infarction

KW - secondary prevention

KW - stroke

UR - http://www.scopus.com/inward/record.url?scp=85068808314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068808314&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.118.024497

DO - 10.1161/STROKEAHA.118.024497

M3 - Article

VL - 50

SP - 1812

EP - 1818

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 7

ER -